12th EDRN Scientific Workshop - Thursday 25 March Agenda
20th Year of EDRN: Making Cancer Detection Possible
Thursday, March 25, 2021 (10:00 a.m. - 7:00 p.m. Eastern Daylight Time)
10:00 a.m. - 10:05 a.m. EDT (all times Eastern Daylight Time) |
Welcome Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Arul Chinnaiyan, MD, PhD, University of Michigan Sudhir Srivastava, PhD, MPH, National Cancer Institute |
10:05 a.m. - 10:25 a.m. EDT |
34: Clinical Perspectives on Biomarker Research Bruce Johnson, MD, Dana-Farber Cancer Institute |
10:25 a.m. - 10:30 a.m. EDT | Q&A |
10:30 a.m. - 11:50 p.m. EDT |
Session 7 - Regulatory, Reimbursement and Entrepreneurship Biomarker Research Moderators: Sudhir Srivastava, PhD, MPH, National Cancer Institute Robert Schoen, MD, University of Pittsburgh Cancer Institute |
10:30 a.m. - 10:45 p.m. EDT |
35: FDA Collaborative on Next Gen Sequencing and its Relevance to Liquid Biopsy for Early Detection James Willey, MD, University of Toledo |
10:45 a.m. - 10:50 a.m. EDT | Q&A |
10:50 a.m. - 11:05 a.m. EDT |
36: Food and Drug Administration Perspective Wendy Rubinstein, MD, PhD, Director of Personalized Medicine |
11:05 a.m. - 11:10 a.m. EDT | Q&A |
11:10 a.m. - 11:25 a.m. EDT |
37: From the Lab to Market: Opportunities from the NCI Small Business Innovation Research (SBIR) Program Michael Weingarten, MA, Director, Small Business Innovation Research, National Cancer Institute |
11:25 a.m. - 11:30 a.m. EDT | Q&A |
11:30 a.m. - 11:50 a.m. EDT | Break |
11:50 a.m. - 12:50 p.m. EDT |
EDRN Poster Highlights Session: Lightning Talks (5 minute Presentations) NCI Program Directors: Lynn Sorbara, PhD, National Cancer Institute Natalie Abrams, PhD, National Cancer Institute |
11:50 p.m. - 11:55 a.m. EDT |
38: GPQuant: An Algorithm for Identification and Quantification of Glycopeptides with Different Glycoforms and Its Application to a Large-scale Quantitative Analysis of Urinary Glycopeptides from Aggressive Prostate Cancer Shao-Yung Chen, PhD, Johns Hopkins University School of Medicine |
11:55 a.m. - 12:00 p.m. EDT |
39: Elevated EVL Methylation Level in Normal Colon Mucosa is a Potential Risk Biomarker for Metachronous Polyps William Grady, MD, Fred Hutchinson Cancer Research Center |
12:00 p.m. - 12:05 p.m. EDT |
40: Radiomics and Its Application in the Stratification of Pancreatic Cystic Lesion(S) Sukhwinder Kaur, PhD, University of Nebraska Medical Center |
12:05 p.m. - 12:10 p.m. EDT |
41: Non-Small Cell Lung Cancer and Peripheral Immunity: Mining the Tumor Macroenvironment Andrew Kossenkov, PhD, The Wistar Institute |
12:10 p.m. - 12:15 p.m. EDT |
42: High Performance in Risk Stratification of Intraductal Papillary Mucinous Neoplasms by EUS-guided Confocal Laser Endomicroscopy Somashekar Krishna, MD, MPH, Ohio State University Medical Center |
12:15 p.m. - 12:20 p.m. EDT |
43: Identification of Autoantibody Biomarkers against Post-Translationally Modified Proteins for the Early Detection of Breast Cancer Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Lusheng Song, PhD, Arizona State University |
12:20 p.m. - 12:25 p.m. EDT |
44: Feasibility of Targeted Proteomics Analysis of Prostate Cancer Progression Biomarkers in FFPE Biopsy Specimens Tao Liu, PhD, Pacific Northwest National Laboratory |
12:25 p.m. - 12:30 p.m. EDT |
45: AI and Methodology Transfer for Early Detection of Tumors Ashish Mahabal, PhD, California Institute of Technology |
12:30 p.m. - 12:35 p.m. EDT |
46: Combining Automated Image Measurements, Blood Biomarkers, and Clinical Data for Improved Decisions in Diagnostic Mammography Jeffrey Marks, PhD, Duke University Medical Center |
12:35 p.m. - 12:40 p.m. EDT |
47: Intermolecular Profiling of Epigenetic Heterogeneity of Rare Biomarkers Chrissy O'Keefe, PhD, Johns Hopkins University |
12:40 p.m. - 12:45 p.m. EDT |
48: Volume Doubling Time and Radiomic Features Predict Tumor Behavior of Screen-Detected Lung Cancers Jaileene Perez-Morales, PhD, H. Lee Moffitt Cancer Center and Research Institute, Inc. |
12:45 p.m. - 12:50 p.m. EDT |
49: Use of the Myprostatescore (MPS) Test for Risk Stratification in Men with a Previous Negative Biopsy: Initial Validation of a Straightforward Testing Approach Michael Sessine, BS, University of Michigan Medical School |
12:50 p.m. - 1:10 p.m. EDT | Break |
1:10 p.m. - 3:10 p.m. EDT | Poster Viewing Session |
3:10 p.m. - 5:00 p.m. EDT | Break |
5:00 p.m. - 7:00 p.m. EDT | Poster/Interactive Session & Lightning Talks from Japan Investigators (AMED P-CREATE) |
5:00 p.m. - 5:50 p.m. EDT | Poster Viewing Session |
5:50 p.m. - 7:00 p.m. EDT | Poster Highlights Session |
5:50 p.m. - 6:00 p.m. EDT |
50: Initial Clinical Trial for Practical Use of Early Diagnosis Marker of Colon Cancer Jun Adachi, PhD, NIBIOHN Japan |
6:00 p.m. - 6:10 p.m. EDT |
51: Possibility for Efficient Pancreatic Cancer Screening Using a Blood Test for Apolipoprotein A2-Isoforms Kazufumi Honda, DDS, PhD, Nippon Medical School |
6:10 p.m. - 6:20 p.m. EDT |
52: Prediction of Cancer Tissue of Origin by Circulating Mirna Profiles Juntaro Matsuzaki, MD, PhD, Keio University Faculty of Pharmacy |
6:20 p.m. - 6:30 p.m. EDT |
53: Identification of Glioblastoma-selective Secreted Proteins by Secretome Analysis, and their CSF levels in GBM patients Sumio Ohtsuki, PhD, Kumamoto University |
6:30 p.m. - 6:40 p.m. EDT |
54: Global Proteomic Analysis of Viable Tissue-Derived Exosomes and Identification of Exo-CAT1 as a Potential Early Detection Marker for Colorectal Cancer Koji Ueda, PhD, Japanese Foundation for Cancer Research |
6:40 p.m. - 6:50 p.m. EDT |
55: Circulating Cancer-Associated Extracellular Vesicles As Early Detection And Recurrence Biomarkers For Pancreatic Ductal Adenocarcinoma Yusuke Yoshioka, PhD, Tokyo Medical University |
6:50 p.m. - 7:00 p.m. EDT |
56: Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility Shingo Kato, MD, PhD, Yokohama City University Hospital |
7:00 p.m. EDT | Adjourn Scientific Workshop |